XKRX
101140
Market cap36mUSD
Oct 08, Last price
4,960.00KRW
1D
-2.36%
1Q
-13.44%
Jan 2017
141.95%
IPO
57.71%
Name
InBioGen Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Pyeongtaek, South Korea, INBIOGEN Co., Ltd. is a footwear manufacturer and distributor founded in 1949. The company produces and sells shoes for children, youth, and adults, serving both the South Korean domestic market and international customers. Its extensive range of products is marketed under several popular brand names, including ARTIS, SPECS, WANGJA, NEOSPEC, and CHAMPION. INBIOGEN Co., Ltd. was formerly known as BTONE CO.,Ltd.
Key people
Tae Jeong Ha
Vice President, Director · since 2010
Seong Yeop Jung
Vice President
Yeong Hun Gwon
Internal Auditor · since 2011
Seong Man Hwang
Internal Auditor · since 2011
Ji Yeon Kang
Director
Jong Hwan Kim
Vice President, Director · since 2011
Byeong Ho Lee
Director · since 2011
Sang Jun Lee
Chief Executive Officer, Director · since 2019
Gyeong Yeol Lee
Director · since 2023
Sang Gil Lee
Director · since 2023
Yeong Seo Park
Director · since 2011
Sang Yeong Won
Managing Director · since 2023
Yeong Gyun Kim
Non-Executive Independent Director · since 2017
Jin Bang Kim
Non-Executive Independent Director · since 2013
Geun Hwan Lee
Non-Executive Independent Director · since 2023
Jae Yeol Lee
Non-Executive Independent Director
Seong Wu Nam
Non-Executive Independent Director · since 2011
Gil Je Ryu
Non-Executive Independent Director · since 2011
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||